## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

In the Matter of Serial No. 76/463,019

Trademark: ERBITUX CETUXIMAB & Antibody Design

Exxon Mobil Corporation,

Opposer,

Opposition No. 91-158,375

٧.

ستدج

Attorney Docket No. 42-060-999

ImClone Systems Incorporated,

Applicant.

**TTAB** 

### **AMENDMENT**

1. Applicant hereby requests that the Board ask the assigned Examining Attorney to amend this application by adding a description of the mark:

> The mark comprises the words ERBITUX CETUXIMAB and an antibody design (shown in stippling).

2. Applicant further requests that the enclosed drawing replace the drawing presently on file.

#### CERTIFICATE OF FIRST CLASS MAILING

The undersigned hereby certifies that the foregoing correspondence addressed to Trademark Trial and Appeal Board, U.S. Patent and Trademark Office, P.D. Box 1451, Alexandria, VA 22313-1451, is being deposited in care and custody of the United States Postal Service by first class mail, postage prepaid on the 29th day of November, 2006.

Dated: New York, New York

November 29, 2006.

11-29-2006

#### REMARKS

The parties, Applicant ImClone Systems Incorporated and Opposer Exxon Mobil Corporation, have reached a settlement in this opposition proceeding. The settlement is based on entry of this amendment, and Exxon Mobil Corporation has consented to the amendment.

The amendment adds a description of the mark, to make clear that the design depicted is a stylized drawing of an antibody. The amendment also substitutes a new drawing for the one presently on file. The difference in the new drawing is that the antibody design is depicted as stippled rather than solid black. Since this does not constitute a material alteration of the mark, Applicant requests that the new drawing be entered of record.

The parties request that the proceedings in this TTAB case remain suspended, pending review of the proposed amendment by the Examining Attorney.

Upon entry of the amendment as requested, Applicant requests that this application be passed to allowance, in view of Exxon Mobil Corporation's having consented thereto.

Respectfully Submitted,

Robert M. Kunstadt Ilaria Maggioni

R. KUNSTADT, P.C.

729 Seventh Avenue, Suite 14B

ANTA. Um

New York, New York 10019

(212) 398-8881

Attorneys for Applicant

Date: 1/29/06

Consented to,

Louis T. Pirkey, Esq.

William G. Barber, Esq.

(see next page

Stephen P. Meleen, Esq.

Pirkey Barber LLP

600 Congress Avenue, Suite 2120

Austin, TX 78701

(512) 322-5200

Attorneys for Exxon Mobil Corporation

Date: 11/26/06

ENC. (new drawing)

Upon entry of the amendment as requested, Applicant requests that this application be passed to allowance, in view of Exxon Mobil Corporation's having consented thereto.

Respectfully Submitted,	Consented to,
Robert M. Kunstadt Ilaria Maggioni R. KUNSTADT, P.C. 729 Seventh Avenue, Suite 14B New York, New York 10019 (212) 398-8881 Attorneys for Applicant	Louis T. Pirkey, Esq. William G. Barber, Esq. Stephen P. Meleen, Esq. Pirkey Barber LLP 600 Congress Avenue, Suite 2120 Austin, TX 78701 (512) 322-5200 Attorneys for Exxon Mobil Corporation
Date:	Date: 11/28/ος

ENC. (new drawing)

# **DRAWING PAGE**

**APPLICANT: ImClone Systems Incorporated** 


ADDRESS: 180 Varick Street, 6th Floor

New York, New York 10014

BASED ON A BONA FIDE INTENTION TO USE THE MARK IN COMMERCE

GOODS: 5 PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL

ANTIBODY FOR THE TREATMENT OF CANCER



## CERTIFICATE OF SERVICE

The undersigned hereby certifies that a true copy of the foregoing AMENDMENT has been served upon:

Louis T. Pirkey, Esq.
William G. Barber, Esq.
Stephen P. Meleen, Esq.
Pirkey Barber LLP
600 Congress Avenue, Suite 2120
Austin, TX 78701

that being the address designated by said attorney for that purpose, by depositing a true copy of same in a postpaid, properly addressed wrapper in an official depository under the exclusive care and custody of the United States Postal Service on November 29, 2006.

MAM. Kunghuri